Avanir Pharmaceuticals, which previously said the FDA had questions about “human factor” study data for a migraine treatment, said it will provide new data.
via WSJ.com: US Business http://ift.tt/1zwxJRr
via WSJ.com: US Business http://ift.tt/1zwxJRr
Nessun commento:
Posta un commento